Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
Vincent T. Martin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert Pallay(Mercer University), Karen Samaan(Eli Lilly (United States)), Xiaoping Li(Eli Lilly (United States)), Chunmei Zhou(Eli Lilly (United States)), Eric Pearlman(University of California, San Francisco), Sheena K. Aurora(Impel Neuropharma (United States))
Cited by 17
Related Papers
Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia
|The Journal of Experimental Medicine|1997|532
CGRP and the Trigeminal System in Migraine
|Headache The Journal of Head and Face Pain|2019|483
N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis
|Nature Communications|2020|453
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP
|Nature Communications|2016|446